


10/10/01



jc812 U.S. PTO

10-12-01

PATENT

Attorney Docket No. DANHSU.001C1

Date: October 10, 2001

Page 1

jc971 U.S. PTO  
09/975143

10/10/01

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

ATTENTION: BOX PATENT APPLICATION

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Daniel K. Hsu, Fu-Tong Liu, Christopher Dowling

For: GALECTIN EXPRESSION IS INDUCED IN CIRRHOTIC LIVER AND HEPATOCELLULAR  
CARCINOMA

Enclosed are:

- (X) 2 sheet(s) of drawing.
- (X) Sequence Listing in 14 pages.
- (X) Sequence Submission Statement.
- (X) Sequence Listing in Computer Readable Format on 1 disk.
- (X) Return prepaid postcard.
- (X) This application is a continuation of international application number PCT/US00/08561, and claims the benefit of priority of international application number PCT/US00/08561 having international filing date of March 29, 2000, designating the United States of America and published in English, which claims the benefit of priority of U.S. provisional patent application no. 60/129,111, filed April 13, 1999; both of which are hereby expressly incorporated by reference in their entireties.
- (X) Incorporation by Reference. The entire disclosure of the prior applications are considered as being part of the disclosure of the accompanying application and are hereby incorporated by reference therein.

The present application qualifies for small entity status under 37 C.F.R. § 1.27. The fees are calculated below:

CLAIMS AS FILED				
FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee			\$370	\$370
Total Claims	33 - 20 =	13 ×	\$9	\$117
Independent Claims	8 - 3 =	5 ×	\$42	\$210
If application contains any multiple dependent claims(s), then add			\$140	\$140
TOTAL FILING FEE		\$837		

- 
- (X) A check in the amount of \$837 to cover the filing fee is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.
- (X) Please use Customer No. **20,995** for the correspondence address.



---

Eric S. Furman, Ph.D.  
Registration No. 45,664  
Attorney of Record

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Hsu, et al.  
Appl. No. : Unknown  
Filed : Herewith  
For : GALECTIN EXPRESSION  
IS INDUCED IN  
CIRRHOTIC LIVER AND  
HEPATOCELLAR  
CARCINOMA  
Examiner : Unknown

**SEQUENCE SUBMISSION STATEMENT**

**ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231**

Dear Sir:


A copy of the Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e) is submitted herewith.

As required by 37 C.F.R. §1821(f), I hereby declare that the information recorded on the enclosed disk is identical to the printed Sequence Listing in the application filed herewith. Accordingly, no new matter has been introduced.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR

Date: 10/10/2001

  
Eric S. Furman, Ph.D.

Registration No. 45,664

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

Eric S. Furman, Ph.D.

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX PATENT APPLICATION

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

**Attorney Docket No.** : DANHSU.001C1

**Applicant(s)** : Hsu, et al.

**For** : GALECTIN EXPRESSION IS INDUCED IN  
CIRRHOTIC LIVER AND  
HEPATOCELLULAR CARCINOMA

**Attorney** : Eric S. Furman, Ph.D.


**"Express Mail"**  
**Mailing Label No.** : EL 842761574

**Date of Deposit** : October 10, 2001

I hereby certify that the accompanying

Transmittal letter; Specification in 45 pages; 2 sheets of drawings; Sequence Listing in 14 pages; Sequence Submission Statement in 1 page; Sequence Listing in Computer Readable Format on 1 disk; Check(s) for Filing Fee(s); Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Carol Macarty

S:\DOCS\ESF\ESF-4321.DOC:sad1  
100901